NASDAQ:OPNT - Nasdaq - US6837501039 - Common Stock - Currency: USD
20.65
-0.12 (-0.58%)
The current stock price of OPNT is 20.65 USD. In the past month the price increased by 2.33%. In the past year, price decreased by -22.31%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
LLY | ELI LILLY & CO | 67.21 | 829.40B | ||
NVO | NOVO-NORDISK A/S-SPONS ADR | 27.44 | 390.99B | ||
JNJ | JOHNSON & JOHNSON | 16.25 | 390.76B | ||
AZN | ASTRAZENECA PLC-SPONS ADR | 20.56 | 230.17B | ||
MRK | MERCK & CO. INC. | 11.71 | 226.40B | ||
NVS | NOVARTIS AG-SPONSORED ADR | 13.77 | 215.98B | ||
PFE | PFIZER INC | 8.46 | 149.04B | ||
SNY | SANOFI-ADR | 13.58 | 136.54B | ||
BMY | BRISTOL-MYERS SQUIBB CO | 48.97 | 113.23B | ||
GSK | GSK PLC-SPON ADR | 7.78 | 74.77B | ||
ZTS | ZOETIS INC | 27.1 | 72.39B | ||
TAK | TAKEDA PHARMACEUTIC-SP ADR | 31.95 | 44.58B |
Opiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The company is headquartered in Santa Monica, California and currently employs 37 full-time employees. The company went IPO on 2017-09-18. The firm developed NARCAN (naloxone hydrochloride) Nasal Spray (NARCAN), a treatment to reverse opioid overdose. The firm's pipeline includes medicines in development for Opioid Overdose Reversal (OOR), Alcohol Use Disorder (AUD), and Acute Cannabinoid Overdose (ACO). The firm is also pursuing other treatment opportunities within the addiction and drug overdose field. Its lead development product is OPNT003 a nasal nalmefene for the treatment of opioid overdose.
OPIANT PHARMACEUTICALS INC
233 Wilshire Blvd, Suite 400
Santa Monica CALIFORNIA 90401 US
CEO: Roger Crystal
Employees: 37
Company Website: https://www.opiant.com/
Phone: 13105985410.0
The current stock price of OPNT is 20.65 USD. The price decreased by -0.58% in the last trading session.
The exchange symbol of OPIANT PHARMACEUTICALS INC is OPNT and it is listed on the Nasdaq exchange.
OPNT stock is listed on the Nasdaq exchange.
7 analysts have analysed OPNT and the average price target is 21.42 USD. This implies a price increase of 3.73% is expected in the next year compared to the current price of 20.65. Check the OPIANT PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
OPIANT PHARMACEUTICALS INC (OPNT) has a market capitalization of 108.80M USD. This makes OPNT a Micro Cap stock.
OPIANT PHARMACEUTICALS INC (OPNT) currently has 37 employees.
OPIANT PHARMACEUTICALS INC (OPNT) has a support level at 20.53 and a resistance level at 20.78. Check the full technical report for a detailed analysis of OPNT support and resistance levels.
The Revenue of OPIANT PHARMACEUTICALS INC (OPNT) is expected to decline by -80.95% in the next year. Check the estimates tab for more information on the OPNT EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
OPNT does not pay a dividend.
OPIANT PHARMACEUTICALS INC (OPNT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-6.55).
ChartMill assigns a technical rating of 5 / 10 to OPNT. When comparing the yearly performance of all stocks, OPNT is a bad performer in the overall market: 63.88% of all stocks are doing better.
ChartMill assigns a fundamental rating of 3 / 10 to OPNT. OPNT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months OPNT reported a non-GAAP Earnings per Share(EPS) of -6.55. The EPS decreased by -13200% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | N/A | ||
ROE | N/A | ||
Debt/Equity | 0.6 |
ChartMill assigns a Buy % Consensus number of 46% to OPNT. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of -2455.56% and a revenue growth -80.95% for OPNT